A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward et al., Global cancer statistics, CA Cancer J Clin, vol.61, pp.69-90, 2011.

A. Vincent, J. Herman, R. Schulick, and R. H. Hruban, Goggins M. Pancreatic cancer. Lancet, vol.378, pp.607-620, 2011.

L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman et al., Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States, Cancer Res, 2014.

, , vol.74, pp.2913-2934

E. M. O'reilly, Pancreatic adenocarcinoma: new strategies for success, Gastrointest Cancer Res, vol.3, pp.11-15, 2009.

T. Conroy, F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, vol.364, pp.1817-1825, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00598658

Y. Pommier, DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition, Chem Rev, vol.109, pp.2894-2902, 2009.

G. L. Rosner, J. C. Panetta, F. Innocenti, and M. J. Ratain, Pharmacogenetic pathway analysis of irinotecan, Clin Pharmacol Ther, vol.84, pp.393-402, 2008.

F. J. Sharom, ABC multidrug transporters: structure, function and role in chemoresistance, Pharmacogenomics, vol.9, pp.105-127, 2008.

M. M. Moasser, The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis, Oncogene, vol.26, pp.6469-6487, 2007.

N. H. Stoecklein, A. M. Luebke, A. Erbersdobler, W. T. Knoefel, W. Schraut et al., Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma, J Clin Oncol, vol.22, pp.4737-4745, 2004.

M. Komoto, B. Nakata, R. Amano, N. Yamada, M. Yashiro et al., HER2 overexpression correlates with survival after curative resection of pancreatic cancer, Cancer Sci, vol.100, pp.1243-1247, 2009.

N. Jonckheere, N. Skrypek, J. Merlin, A. F. Dessein, P. Dumont et al., Van Seuningen I. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways, PLoS One, vol.7, p.32232, 2012.

N. Skrypek, B. Duchene, M. Hebbar, E. Leteurtre, I. Van-seuningen et al., The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family, Oncogene, vol.32, pp.1714-1723, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00807837

M. J. Labonte, P. C. Manegold, P. M. Wilson, W. Fazzone, S. G. Louie et al., The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38, Int J Cancer, vol.125, pp.2957-2969, 2009.

I. Vannini, W. Zoli, F. Fabbri, P. Ulivi, A. Tesei et al., Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines, Anticancer Drugs, vol.20, pp.918-925, 2009.

C. Lu, F. Zhu, Y. Y. Cho, F. Tang, T. Zykova et al., Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3, Mol Cell, vol.23, pp.121-132, 2006.

L. Zhang, J. S. Davis, S. Zelivianski, F. F. Lin, R. Schutte et al., Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment, Cancer Lett, vol.285, pp.58-65, 2009.

M. Yamade, M. Sugimoto, M. Nishino, T. Uotani, S. Sahara et al., Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence, Anticancer Res, vol.32, pp.105-114, 2012.

Y. Pommier, Topoisomerase I inhibitors: camptothecins and beyond, Nat Rev Cancer, vol.6, pp.789-802, 2006.

C. Fiorini, M. Cordani, C. Padroni, G. Blandino, D. Agostino et al., Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine, Biochim Biophys Acta, vol.1853, pp.89-100, 2015.

C. Fiorini, M. Menegazzi, C. Padroni, I. Dando, D. Pozza et al., Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis, Apoptosis, vol.18, pp.337-346, 2013.

M. T. Rosenfeldt, J. O'prey, J. P. Morton, C. Nixon, G. Mackay et al., p53 status determines the role of autophagy in pancreatic tumour development, Nature, vol.504, pp.296-300, 2013.

N. Jonckheere and A. Vincent, Van Seuningen I. Of autophagy and in vivo pancreatic carcinogenesis: the p53 status matters, Clin Res Hepatol Gastroenterol, vol.38, pp.423-425, 2014.

F. Lozy, X. Cai-mcrae, I. Teplova, S. Price, A. Reddy et al., ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss, Autophagy, vol.10, pp.662-676, 2014.

E. F. Wagner and A. R. Nebreda, Signal integration by JNK and p38 MAPK pathways in cancer development, Nat Rev Cancer, vol.9, pp.537-549, 2009.

L. Catley, Y. T. Tai, R. Shringarpure, R. Burger, M. T. Son et al., Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma, Cancer Res, vol.64, pp.8746-8753, 2004.

H. Yu, J. Park, J. Lee, K. Choi, and C. Choi, Constitutive Expression of MAP Kinase Phosphatase-1 Confers Multidrug Resistance in Human Glioblastoma Cells, Cancer Res Treat, vol.44, pp.195-201, 2012.

B. R. Davies, A. Logie, J. S. Mckay, P. Martin, S. Steele et al., AZD244 (ARRY-14288), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models, Mol Cancer Ther, vol.6, pp.2209-2219, 2007.

G. Szakacs, J. K. Paterson, J. A. Ludwig, C. Booth-genthe, and M. M. Gottesman, Targeting multidrug resistance in cancer, Nat Rev Drug Discov, vol.5, pp.219-234, 2006.

L. Candeil, I. Gourdier, D. Peyron, N. Vezzio, V. Copois et al., ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases, Int J Cancer, vol.109, pp.848-854, 2004.

T. Mazard, A. Causse, J. Simony, W. Leconet, N. Vezzio-vie et al., Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump, Mol Cancer Ther, vol.12, pp.2121-2134, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00861055

B. Mohelnikova-duchonova, V. Brynychova, M. Oliverius, E. Honsova, Z. Kala et al., Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues, Pancreas, vol.42, pp.707-716, 2013.

H. S. Kim, N. C. Kim, K. H. Chae, G. Kim, W. S. Park et al., Expression of multidrug resistance-associated protein 2 in human gallbladder carcinoma, Biomed Res Int, p.527534, 2013.

A. Maciejczyk, E. Jagoda, T. Wysocka, R. Matkowski, B. Gyorffy et al., ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome, Pathol Oncol Res, vol.18, pp.331-342, 2012.

S. H. Lee, H. Kim, J. H. Hwang, H. S. Lee, J. Y. Cho et al., Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients, Pathol Int, vol.62, pp.167-175, 2012.

A. Mishra and M. Verma, Cancer biomarkers: are we ready for the prime time? Cancers (Basel), vol.2, pp.190-208, 2010.

E. P. Diamandis, Cancer biomarkers: can we turn recent failures into success?, J Natl Cancer Inst, vol.102, pp.1462-1467, 2010.

N. Jonckheere, M. Perrais, C. Mariette, S. K. Batra, J. P. Aubert et al., Van Seuningen I. A role for human MUC4 www.impactjournals.com/oncotarget mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis, Oncogene, vol.23, pp.5729-5738, 2004.

J. Torrisani, B. Bournet, M. C. Du-rieu, M. Bouisson, A. Souque et al., , p.7

, MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression, Hum Gene Ther, vol.20, pp.831-844, 2009.

N. Jonckheere, V. Fauquette, L. Stechly, N. Saint-laurent, A. S. Susini et al., Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression, Br J Cancer, vol.101, pp.637-644, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00410436

G. Piessen, N. Jonckheere, A. Vincent, B. Hemon, M. P. Ducourouble et al., Van Seuningen I. Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepatocyte nuclear factor 1alpha, Biochem J, vol.402, pp.81-91, 2007.

I. Van-seuningen, M. Perrais, P. Pigny, N. Porchet, J. Aubert et al., Van Seuningen I. The murine Muc2 mucin gene is transcriptionally regulated by the zinc-finger GATA-4 transcription factor in intestinal cells, 43. van der Sluis M, vol.348, pp.952-960, 2000.